Japan· JP-4291051F1022
パルボシクリブ
A palbociclib product containing パルボシクリブ, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Palbociclib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EF01 (palbociclib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 8 of them publish a price we can compare per daily dose
Palbociclib · ATC L01EF01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palbociclib costs, country by country.
Normalised to the WHO defined daily dose (94 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palbociclib · price per daily dose (94 mg)
USD · FX 28 Sept 2026
- CH Switzerland$155.65
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- パルボシクリブ
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- L01EF01
- ATC class
- Palbociclib
- Defined daily dose
- 94 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
340 interactions on record for palbociclib.
Graded by severity as the source publishes them — 74 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Palbociclib · interactions on record
340 records
- 74 severe
- 256 moderate
- 10 minor
Most severe, free to view
- LonafarnibA16AX20severe
- BerotralstatB06AC06severe
- ConivaptanC03XA02severe
- KetoconazoleH02CA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EF01
Palbociclib, as other registers publish it.
- NetherlandsIbaclib 100 mg, filmomhulde tablettenElpen Pharmaceutical Co. Inc.
- NetherlandsIbaclib 125 mg, filmomhulde tablettenElpen Pharmaceutical Co. Inc.
- NetherlandsIbaclib 75 mg, filmomhulde tablettenElpen Pharmaceutical Co. Inc.
- DenmarkIbrancePfizer Europe MA EEIG
- United StatesIbrancePfizer Laboratories Div Pfizer Inc
- United StatesIbranceU.S. Pharmaceuticals
- NorwayIbrancePfizer Europe MA EEIG (1)
- United StatesIbranceU.S. Pharmaceuticals
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0f26a66-7753-4cb8-89d0-1af0f8f79d01 GET /v1/drugs/d0f26a66-7753-4cb8-89d0-1af0f8f79d01?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "25mg1錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291051F1022",
"category": "内用薬",
"price_yen": 5076.8,
"generic_name": "パルボシクリブ",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about palbociclib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.